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Antineutrophil cytoplasmic antibodies to proteinase 3 in Weg- spiratory tract, systemic vasculitis affecting small blood
ener’s granulomatosis: Epitope analysis using synthetic pep- vessels, and pauci-immune–necrotizing crescentic glo-
tides. merulonephritis [1] together with the presence of anti-Background. Antineutrophil cytoplasmic antibodies (ANCA)
neutrophil cytoplasmic antibodies (ANCAs) in almostto proteinase 3 (PR3) are strongly associated with Wegener’s
all of the patients [2]. The latter finding suggests angranulomatosis (WG) and are thought to be involved in its
pathogenesis. Levels of PR3-ANCA do not always correspond autoimmune pathogenesis. The target antigen for ANCA
to clinical disease activity nor to functional effects of these in WG has been identified as proteinase 3 (PR3) [3–5],
antibodies in vitro, suggesting differences in epitope specificity. which is one of the four serine proteases in the azurophi-To define relevant epitopes for PR3-ANCA, sera of WG pa-
lic granules of neutrophilic granulocytes and monocytestients were analyzed on their reactivity to linear peptides of
[6]. PR3-ANCA has been established as a specific markerPR3.
Methods. Fifty linear peptides of 15 amino acids in length for WG, and detection of these autoantibodies is helpful
with an overlap of 10 aa spanning the entire PR3 sequence in the diagnosis and follow-up of WG patients [7, 8].
were synthesized. Sera of 27 WG patients with active disease Although the etiology of WG is still unknown, severaland 27 age- and sex-matched healthy controls, eight anti-PR3
observations suggest that PR3-ANCAs are involved inmonoclonal antibodies (mAbs), and a rabbit anti-PR3 serum
the pathogenesis of WG [9]. First, titers of PR3-ANCAwere tested by enzyme-linked immunosorbent assay for reac-
tivity to PR3 peptides. rise prior to a relapse of WG in many patients [7, 10,
Results. Rabbit anti-PR3 serum recognized three distinct 11], but these data have been disputed by others [12, 13].
peptide areas, whereas none of the anti-PR3 mAbs bound
In addition, PR3-ANCA can bind to PR3 expressed onPR3 peptides. Sera of both WG patients and healthy controls
the cell surface of primed neutrophils and subsequentlyrecognized a restricted number of PR3 peptides. Four of these
peptide areas were recognized significantly more strongly by activate these cells. Upon activation, neutrophils pro-
WG sera than by control sera. Sera drawn at the initial presen- duce reactive oxygen radicals and degranulate lysosomal
tation of WG mainly recognized these peptides. Two of the enzymes, including PR3 [14, 15]. Finally, PR3-ANCA
recognized peptide areas were located near the active center
can interfere with PR3 proteolytic activity as well as withof PR3.
the binding of the natural inhibitor a1-antitrypsin to PR3Conclusion. A restricted number of epitope areas of PR3
are recognized both by WG patient sera and control sera. Four [16–18]. Data from a relatively small group of patients
peptide areas were bound stronger by sera of WG patients at show that the previously-mentioned functional charac-
initial presentation than by healthy controls. teristics of PR3-ANCA correlate stronger with disease
activity than the ANCA titer alone [18, 19]. These data
Wegener’s granulomatosis (WG) is characterized by suggest that differences in pathogenic potential of
granulomatous inflammation in the upper and lower re- ANCA may be related to differences in epitope specific-
ity of these antibodies.
Elucidation of the epitopes recognized by PR3-ANCAKey words: ANCA, inflammation, necrotizing crescentic glomerulone-
phritis, serine proteinase, linear epitopes on PR3. using recombinant or modified PR3 has proved to be
difficult [20]. Antibody binding is abrogated by denatur-Received for publication January 24, 2000
ing the antigen and by reducing its disulfide bondsand in revised form June 13, 2000
Accepted for publication July 18, 2000 [20, 21]. Despite this apparent requirement for an intact
tertiary structure, there are three reports of PR3-ANCAÓ 2001 by the International Society of Nephrology
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binding to linear peptides (abstract; Griffith, Vasc Dif- Serum IgG concentrations were determined by nephe-
lometry. Clinical and laboratory data of the patients arefuse Lung Dis 13:256, 1996) [21, 22]. Two reports identi-
fied distinct epitope regions that were bound by PR3- outlined in Table 1. Sera from 27 age- and sex-matched
healthy blood donors were used as controls. These seraANCA (abstract; Griffith, Vasc Diffuse Lung Dis 13:256,
1996) [22]. However, in one report, no binding of PR3- were negative for ANCA by IIF, capture ELISA for
PR3, MPO and HLE, and PR3-specific direct ELISA.ANCA to linear peptides could be detected because of
a high aspecific binding [21]. Sera from three patients with early rheumatoid arthritis
and sera from three patients with a relapse of systemicThe former studies used peptides that were formed
by coupling amino acids on pins [21, 22]; sequence and lupus erythematosus were tested as disease controls.
purity of these peptides can be checked only after re-
ANCA detectionmoval from the pins. Using this system, sera of healthy
and disease controls also bound to linear peptides of Antineutrophil cytoplasmic antibodies were detected
by IIF on ethanol-fixed granulocytes according to a stan-PR3 [21, 22]. Few clinical data were given on the sera
tested, so any relationship between peptide recognition dard protocol [2, 26] with minor modifications [27]. Pa-
tient and control sera were tested at serial twofold dilu-and clinical or laboratory features of disease could not
be analyzed. tions starting at a dilution of 1:20. Slides were read by
two independent observers, and titers of $1:40 wereThe aim of the present work was to identify possible
linear epitopes on PR3 recognized by PR3-ANCA of considered positive for ANCA.
Specificity for PR3, MPO, or HLE was defined bydefined patients with WG as well as of age- and sex-
matched healthy controls. Furthermore, monoclonal an- antigen-specific capture ELISA, as previously described
[28]. Sera were considered positive when values ex-tibodies (mAbs) to PR3 and a rabbit anti-PR3 serum
were tested in order to compare findings in patients with ceeded the mean 1 2 SD of normal controls (N 5 50).
Titers of PR3-ANCA were also assessed by antigen-those originating from an immune response to an exoge-
nous antigen in experimental animals. Binding was deter- specific direct ELISA [29]. In this ELISA, a standard
PR3-ANCA serum was defined as 100 units, and themined by enzyme-linked immunosorbent assay (ELISA)
in which soluble peptides were used, and sequence and sera tested were calculated accordingly. Titers of six units
or more were considered positive for PR3-ANCA, basedquality control of peptides prior to use were performed.
We provide evidence that PR3-ANCA sera as well as on results of normal controls.
healthy control sera bind specifically to a restricted num-
Purification of PR3ber of linear PR3 epitopes, two of which are located
near the active site. The rabbit anti-PR3 serum recog- Proteinase 3 was purified according to the isolation
procedure of Leid et al [30] with minor modifications.nized three distinct peptide areas that partly overlapped
with the areas recognized by PR3-ANCA sera. Enriched leukocyte populations were obtained from the
Blood Bank of Groningen (The Netherlands) and were
pooled and suspended in phosphate-buffered saline
METHODS
(PBS). Red blood cells were lyzed, and leukocytes were
Patients and controls collected. Cells were disrupted by nitrogen cavitation at
48C for 20 minutes at 350 psi (Parr Instruments Co.,Sera were obtained from 27 patients with diagnosis
of WG established according to clinical and histologic Moline, IL, USA). Next, granules were separated by
discontinuous Percoll gradient (Pharmacia, Uppsula,criteria [1]. Patients fulfilled the American College of
Rheumatology criteria for WG [23]. All patients had Sweden), and a granules were pooled and disrupted in
PBS with 2% Triton for 30 minutes at 378C. The granuleactive disease, either newly developed or relapsing at the
time of testing. Active disease was defined as previously extract was applied to a Biorex-70 column (Bio-Rad
Laboratories, Richmond, CA, USA). PR3-positive anddescribed [24, 25]. A distinction was made between lim-
ited (N 5 9) and generalized (N 5 18) disease activity HLE- and MPO-negative fractions were pooled and con-
centrated by aquazide II (Calbiochem, La Jolla, CA,based on the absence or presence of renal involvement,
respectively. Most of the patients did not receive any USA). The concentrate was applied to a Superdex-75
column (Pharmacia). PR3-positive fractions were pooledimmunosuppressive treatment at the time of serum sam-
pling. One patient received pulse treatment of methyl- and concentrated by aquazide II. PR3 was not contami-
nated with HLE, MPO, or cathepsin G as tested byprednisolone. Sera from all patients were tested for
ANCA by indirect immunofluorescence (IIF) on etha- ELISA and immunoblot (data not shown).
nol-fixed granulocytes and by ELISA for PR3, myeloper-
Antibodiesoxidase (MPO), and human leukocyte elastase (HLE;
discussed later in this article). One patient (patient 1) In this study, eight mAbs to PR3 were used. MAb
12.8 has been produced by Goldschmeding et al and ishad antibodies directed against PR3 as well as MPO.
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Table 1. Patient characteristics
Disease Serum
Patient Disease duration c-ANCA PR3-ANCA CRP Creatinine Serum IgG
no. Sex Age extension months IIF titera unitsd mg/mL lmol/L mg/mL Treatment
1 m 64 G NP .640 482 384 211 22.2 No
2 f 53 L NP 160 227 37 81 22.5 No
3 m 78 G NP .640 13 163 136 13.2 No
4 m 72 G NP 160 499 19 272 10.9 No
5 m 45 L NP 80 312 96 97 14.9 No
6 f 59 G NP 160 162 29 184 20.9 Pred, 20 mga
7 f 70 G NP .640 361 122 480 13.3 No
8 m 58 G NP 320 633 31 268 20.1 No
9 f 50 L NP 160 16 111 74 15.2 No
10 f 24 G NP 160 227 315 68 10.6 No
11 m 71 G NP 320 247 190 243 23.1 No
12 f 71 L NP 20 33 25 68 18.2 No
13 m 19 L NP 160 353 4 76 13.2 No
14 m 47 G NP 640 2933 39 113 16.2 No
15 f 56 G NP 320 327 58 204 7.7 No
16 m 38 G NP 640 324 38 106 8.9 Pred, 1000 mgb
1 CP, 175 mgc
17 m 80 G 7 320 272 23 455 11.7 Pred, 10 mg
18 f 52 L 13 40 37 8 88 11.0 Pred, 60 mg
19 m 67 G 15 160 12 100 143 19.6 Pred, 7.5 mg
20 m 54 G 20 320 900 ,4 139 13.7 CP, 50 mg
21 m 71 G 21 .640 160 151 279 7.17 Aza, 25 mg
22 f 50 L 27 .640 258 21 73 10.6 No
23 m 50 L 82 160 25 7 102 12.4 No
24 f 71 G 118 .640 445 50 164 14.4 No
25 f 56 L 139 160 68 24 101 7.58 Aza, 150 mg
26 m 44 G 146 640 500 53 110 14.4 No
27 m 70 G 166 320 47 54 222 13.1 Aza, 100 mg
Abbreviations are: m, male; f, female; L, limited; G, generalized; NP, newly diagnosed patient; c-ANCA IIF titer, cytoplasmic ANCA titer measured by indirect
immunofluorescence; PR3-ANCA, proteinase 3-antineutrophil cytoplasmic antibodies titer measured by direct ELISA in displayed units; Treatment, immunosuppres-
sive treatment; No, no treatment; Aza, azathioprine; Pred, prednisolone/day; CP, cyclophosphamide.
a Treatment for 3 months
b Single pulse treatment 2 days before sampling
c Treatment for 2 days
d IIF titers of $1:40 were and PR3-ANCA titers of $6 units are considered positive for PR3-ANCA
available at the CLB (Amsterdam, the Netherlands) [3]. lap of 10 amino acids. At the N-terminus of each peptide,
a cysteine residue was present. This residue was eitherDr. J. Wieslander (Wieslab, Lund, Sweden) provided
MAbs 4A3 and 4A5 [31]. The mAbs Hz1F12 (abstract; supplementary (c-) or part of the normal PR3 sequence
(C). These peptides were synthesized at the peptide cen-Haung, Clin Exp Immunol 101:501, 1995) and MC-PR3-2
[32] were obtained from the late Dr. C.M. Lockwood ter of the research school of infection and immunity,
Veterinary Faculty (Utrecht, The Netherlands). Peptides(Cambridge, UK) and Dr. U. Specks (Rochester, MN,
USA), respectively. MAbs PR3G-2, PR3G-3, and PR3G-4 were prepared by automated simultaneous multiple pep-
tide synthesis (SMPS) [35]. The SMPS setup was devel-were produced in our laboratory [33]. Isotype-matched
mAbs directed against either rat intercellular adhesion oped using a standard autosampler (Gilson 221) as de-
scribed previously [35]. Briefly, standard Fmoc chemistrymolecule or a protein of human cytomegalovirus (pp65)
were used as negative control. A homemade rabbit poly- with in situ PyBop/NMM activation of the amino acid
in a fivefold molar excess with respect to 2 mol/peptideclonal antibody against PR3 (Rb anti-PR3) was used as
a positive control, and normal rabbit serum was used as PAL-PEG-PS resin (PerSeptive Biosystems, Foster City,
a negative control. CA, USA) was employed. Peptides were obtained as
C-terminal amides after cleavage with 90 to 95% trifluor-
Synthesis of peptides acetic acid (TFA)/scavenger cocktails. The composition
and purity of the peptides was checked by reverse-phaseFifty overlapping peptides were synthesized from the
sequence of human PR3 [34]. All overlapping peptides high-performance liquid chromatography (RP-HPLC)
and ion-trap mass spectrometry.of human PR3 are listed in Figure 1. The overlapping
peptides were 15 amino acids long, except for peptides The sequence of PR3 [34] used to design the peptides
in this study differed in three amino acids from the se-39 and 49, which contained 16 amino acids, and peptide
38 being 17 amino acids long. The peptides had an over- quence of PR3 [36] used in other studies on binding of
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Fig. 1. Diagram illustrating the 50 linear peptides spanning the sequence of proteinase 3 (PR3). Numbering of the amino acids is according to
the sequence of PR3 published by Campanelli et al [36]. Residue numbers 227 to 23 constitute the signal sequence; 22 to 21, the prosequence,
1 to 222 the mature form of PR3; residue 222 to 229 the C-terminal domain. Residues of the catalytic triad H44, D91, and S176 are marked by gray
boxes. Peptide numbers are typed in front of each sequence. At the N terminus of each peptide a cysteine residue is present, this residue was
either supplementary (c-) or part of the normal PR3 sequence. The three amino acids that were different in the PR3 sequence used in this study
compared with other studies are underlined.
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PR3-ANCA to linear peptides of PR3 (abstract; Griffith, binding of purified IgG to peptides together with its re-
spective serum was tested. Purified IgG was used at anVasc Diffuse Lung Dis 13:256, 1996) [21, 22]. This poly-
morphism in the PR3 gene has been reported recently IgG concentration of 200 mg/mL, which is more or less
comparable to the total concentration as present in a[37]. These amino acids are underlined in Figure 1. As
two of these variant amino acids, that is, amino acids 108 1:50 diluted serum sample as used in the ELISAs.
and 109, were part of an important epitope recognized
Statistical analysisby PR3-ANCA sera [22]; peptides 26 to 28 were also
synthesized with an alanine (A) and threonine (T) at Differences in OD values between PR3-ANCA sera
and healthy controls were tested by Mann–Whitneypositions 108 and 109.
U test. Sera of patients with initial presentation or relapse
Peptide ELISA of WG were compared with respect to OD values ob-
tained in the peptide ELISA, units in the direct ELISA,The cys-peptides were covalently coupled to Covalink
NH plates (Nunc, Roskilde, Denmark) to be described titers of IIF, serum IgG concentrations, levels of C-reac-
tive protein (CRP), and serum creatinine levels by theelsewhere (van der Zee et al, unpublished data). The
NH-reactive groups were modified with 0.5 mmol/L 3-(2- Mann–Whitney U test. Correlation between OD values
obtained in the peptide ELISA and units in the directpyridyldithio) propionacid N-hydroxysuccinimide ester
(SPDP; Sigma, Zwijndrecht, The Netherlands) into an ELISA, titers of IIF, and serum IgG concentrations were
analyzed by the Spearman rank correlation test. Theactive thiol group [38]. The active thiol group was used
for covalent coupling of peptides with an N-terminal level of significance used was 0.05. All reported P values
are two sided.cysteine residue. After 30 minutes, plates were washed
in sterile water, and peptides (15 mg/mL), diluted in 0.1
mol/L Tris-HCl, pH 8.0, were incubated for one hour.
RESULTS
After washing in sterile water, plates were blocked for
Rabbit anti-PR3 serum15 minutes in 200 mL/well of 300 mmol/L NaCl, 100
mmol/L Tris-HCl, and 0.25% bovine serum albumin Rabbit serum raised against PR3 bound to three
groups of linear peptides of PR3, whereas normal rabbit(BSA). Plates were washed in washing buffer (150
mmol/L NaCl, 10 mmol/L Tris-HCl, and 0.05% Tween- serum did not bind to any of the linear peptides (Fig.
2A). Rb anti-PR3 bound to the peptides in a highly20). Next, plates were incubated with either PR3-ANCA
sera (1:50), healthy control sera (1:50), Rb anti-PR3 restricted manner. Peptides 6 and 7, located at the
N-terminus of the mature protein, and peptides 28 to 30(1:4000), or anti-PR3 mAbs (concentration mAbs 0.1 to
0.5 mg/mL, and PR3G-4 8 mg/mL) in 450 mmol/L NaCl, and 32 to 34 were recognized. These areas are not located
near the active site of PR3. The amino acid stretches100 mmol/L Tris-HCl, 0.25% BSA, 1% normal goat se-
rum, and 0.05% Tween-20. Then either goat anti-human recognized were surface accessible [39]. The peptide
ELISA with this antibody proved reproducible, as exper-IgG (1:1500; American Qualex, San Clemente, CA,
USA), goat anti-rabbit IgG (1:500; Sigma) or affinity- iments repeated up to three times gave similar results.
purified goat anti-mouse IgG (1:500; Sigma) was added.
Monoclonal antibodiesAll antibodies were alkaline-phosphatase (AP) conju-
gated. Finally, p-nitrophenyl phosphate (Sigma) in 1 Anti-PR3 mAbs did not bind to linear PR3 peptides,
but did bind to whole PR3. The OD values obtained formol/L diethanolamine, pH 9.8, was used as substrate,
and color development was measured at 405 nm. One the anti-PR3 mAbs on peptides were low and similar to
the subclass-specific control mAbs. The goat anti-mousewell was always coated with PR3 inactivated by phenyl-
methylsulfonyl fluoride (PMSF; Sigma) as a positive con- IgG AP conjugate when used alone gave similar results
as anti-PR3 mAbs (data not shown).trol, and in one well, peptides were omitted as a blank
value. Of the wells coated with PR3 the mean optical
Patients and control seradensity (OD) value 1 2 SD of healthy control sera was
used as cut-off value for a positive reaction of patient Twenty-seven patients with WG were studied. All pa-
tients had active disease, either during their initial pre-sera. The OD values obtained with this blank were sub-
tracted from the OD values obtained with the peptides. sentation of WG (N 5 16) or during relapsing disease
(N 5 11). All WG sera recognized PR3 bound to covalinkReaction on peptides was considered positive when the
median of the OD values of PR3-ANCA sera or healthy NH plates, whereas sera of healthy controls, except for
one, did not (Fig. 3). OD values obtained for PR3-ANCAcontrol sera after subtraction of the blanks exceeded an
arbitrary value of 0.5. The goat anti-human IgG, goat sera in this assay correlated with the units obtained by
direct PR3 ELISA given in Table 1 (r 5 0.52, P 5 0.006).anti-rabbit IgG, and goat anti-mouse IgG AP-conjugated
secondary antibody, when used alone, did not produce Sera of WG patients and healthy controls recognized
linear peptides in a similar pattern (Fig. 4). Interestingly,any binding with the linear peptides. In one experiment,
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Fig. 2. Peptide ELISA with rabbit serum raised against proteinase 3 (PR3), purified IgG, and serum of a Wegener’s granulomatosis (WG) patient.
Fifty overlapping peptides (15 mg/mL) spanning the entire sequence of PR3 were coupled on covalink-NH plates. PR3 was coupled as a positive
control and wells without peptide (blank) were used as blank values. (A) Rabbit anti-PR3 (j) or normal rabbit serum (h) were used at a 4000-
fold dilution. (B) Serum of WG patient 1 (j) or purified IgG from WG patient 1 (h) was used at a 50-fold serum dilution or 200 mg/mL IgG
concentration, respectively. On the x axis, peptide numbers are given according to the sequence in Figure 1. On the y axis, the OD values measured
at 405 nm are depicted.
all sera bound to five distinct peptide areas (peptide ments repeated up to three times with a few patient and
control sera gave similar results. The binding of serumnumbers 7 to 11, 13 to 14, 31 to 32, 36 to 37, and 39 to
40) and bound to some single peptides (peptide number sample from patient 1 with its respective purified IgG
sample is shown in Figure 2B. Purified IgG bound to the1, 28, and 44). This is shown also in Table 2 (second
column); reactivity to peptide number 28 was not termed same peptides as its respective serum sample. The similar
pattern in binding of WG and control sera could not be“1” because the median of OD values did not exceed 0.5.
The peptide ELISA proved reproducible, as experi- explained by binding of the secondary antibody to the
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both groups. No difference in binding to PR3 peptides
was seen between patients with a limited or generalized
presentation of WG. The peptide areas recognized by
human sera partly overlapped the areas recognized by
Rb anti-PR3 (Fig. 2A), as peptides 7 and 32 were bound
both by Rb anti-PR3 serum and human sera. Peptides
7 and 32 were not located near the active site of PR3
(Fig. 1).
Two of the peptide areas that were more strongly
bound by WG sera than by control sera (peptide num-
bers 13-14, 39-40) were located near the active center of
PR3 at the active site H44 and S176, respectively (Fig. 1).
Peptide area 7-11 is located at the N-terminus of PR3
Fig. 3. ELISA on covalink-NH plates with whole PR3 with sera from (Fig. 1). All peptides recognized were surface accessible
PR3-ANCA–positive patients and healthy controls. PR3 was coupled [39]. These four identified peptide areas coincided to
on covalink-NH plates as a positive control. PR3-ANCA positive sera
some extent with earlier described epitopes recognized(d) or sera from healthy controls (s) were used at a 50-fold dilution.
On the y axis the OD values measured at 405 nm are depicted. The by PR3-ANCA sera (Table 2; sixth column).
mean is shown for PR3-ANCA–positive and healthy control sera. Hori- The amino acid sequences of the four peptide areas
zontal line represents the mean 1 2 SD values of healthy controls,
that were bound more strongly by PR3-ANCA than bywhich were taken as cut-off value for a positive reaction.
control sera were checked on protein similarity in
Swissprot using blast 2.0 [40]. The amino acid sequences
were highly specific for serine proteases. Serine proteases
peptides, as incubation of the secondary antibody alone with the highest amino acid homology with these four
did not produce binding to any of the peptides. In addi- identified peptide areas were HLE [41], human medul-
tion, binding of PR3-ANCA sera to different PR3 pep- lasin [42], and murine PR3 [43, 44]. In addition, the
tides did not correlate with levels of total IgG in these sequences of the other peptides that were bound by sera
sera nor with levels of PR3-ANCA as determined by also were highly specific for serine proteases.
IIF, direct PR3 ELISA (Table 1), or ELISA with PR3 The sequence of PR3 [34] used to design the peptides
on NH covalink plates (Fig. 3). Of two patients, the in this study differed by two amino acids from the se-
reactions of different serum samples were tested on their quence of PR3 [36] used in other studies (abstract; Grif-
binding to linear peptides. The different serum samples fith, Vasc Diffuse Lung Dis 13:256, 1996) [21, 22]. These
preferentially bound to the same peptides for an individ- two variant amino acids were part of an important epi-
ual patient (data not shown). tope recognized by PR3-ANCA sera [22]. Therefore,
Furthermore, sera of three patients with a relapse of binding of sera of WG patients and healthy controls was
systemic lupus erythematosus and sera of three patients also tested on peptide numbers 26-28 with T108 and S109
with early rheumatoid arthritis bound to similar peptides substituted for alanine and threonine, respectively [37].
as sera from WG patients and healthy controls. The me- Peptides 26-28 variants showed similar binding of PR3-
dian OD values obtained by these six sera were not en- ANCA as peptides 26-28 without amino acid substitu-
hanced compared with the OD values found in patients tions (data not shown).
with WG and healthy controls (data not shown).
Within the five peptide areas that were bound by WG
DISCUSSIONand control sera, four peptide areas were recognized
significantly better by WG sera than by healthy controls This study, using overlapping linear peptides spanning
the entire sequence of PR3, shows that PR3-ANCA sera(Table 2, third column). This difference in recognition
could mainly be attributed to sera of patients with initial of patients with active WG as well as healthy control
sera bind to a restricted number of linear PR3 peptides,presentation of WG (Table 2). Differences between sera
of patients with initial presentation or relapse of WG in two of which are located near the active center of PR3.
Four peptide areas were bound significantly stronger bybinding to peptide numbers 7-10, 14-15, 31-32, and 38-40
are depicted in more detail in Figure 5. These differences sera of WG patients at initial presentation than by
healthy controls. The polyclonal rabbit anti-PR3 serumbetween sera of patients with initial presentation or re-
lapse of WG were not observed for PR3-ANCA titers recognized three distinct peptide areas that partly over-
lapped with the areas recognized by PR3-ANCA sera.determined by either IIF, direct ELISA, or ELISA per-
formed on NH covalink plates with PR3 (Fig. 5). Also, Anti-PR3 mAbs did not bind to linear PR3 peptides.
Distinct peptide areas and single peptides were recog-total IgG concentrations or clinical data like CRP levels
and/or serum creatinine levels did not differ between nized both by sera of WG patients and healthy controls.
Fig. 4. Peptide ELISA with PR3-ANCA–positive sera of patients with WG and sera of age- and sex-matched healthy controls. Fifty overlapping
peptides spanning the entire sequence of PR3 were coupled on covalink-NH plates. Wells without peptide (blank) were used as blank values and
subtracted from the optical density (OD) values obtained on wells with peptides. PR3-ANCA–positive sera (d) or sera from healthy controls (s)
were used at a 50-fold dilution. On the x axis peptide numbers are given according to the sequence in Figure 1. On the y axis, the OD values
measured at 405 nm are depicted. Reactivity was defined as “1” when median OD values of sera .0.5. Peptide areas recognized by sera are
marked with a line and number.
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Table 2. Overview on peptides recognized and the significant differences in binding to linear peptides of PR3 between sera of patients with
Wegener’s granulomatosis and healthy controls
Reaction on peptides
Peptide All patientsb Initial presentationc Relapsed Previous
number OD valuesa N 5 27 N 5 16 N 5 11 studies
1 1/2
2 2 *
3 2 * *
4 2 *** **
5 2 * W
6 2 * * W/G
7 1/1 ** ** W/G
8 1/2 *** ** W/G
9 1/1 * **
10 1/1 ** **
11 1/1
12 2
13 1/1
14 1/2 *** **** G
15 2 * G
16 2 ** * G
17 2
18 2
19 2 W
20 2 W
21 2
22 2
23 2
24 2
25 2
26 2
27 2 W
28 2 * W
29 2 W
30 2 * * W
31 1/1 ** ** G
32 1/2 ** * W/G
33 2 W
34 2
35 2
36 1/1 W
37 1/1 W
38 2 * * W/G
39 1/2 * ** W/G
40 1/2 ** * * W
41 2 W
42 2
43 2 W
44 1/2 W
45 2 * G
46 2 G
47 2 G
48 2 *
49 2 G
50 2 G
Abbreviations are: W, linear peptides reacting with PR3-ANCA sera as identified by Williams et al [22]; G, linear peptides reacting with PR3-ANCA sera as
identified by Griffith et al (abstract; Griffith ME, Vasc Diffuse Lung Dis 13:256, 1996)
a 1/1 5 median OD values of PR3-ANCA and healthy control sera .0.5; 1/2 5 median OD values of PR3-ANCA .0.5 and median OD values of healthy
control sera ,0.5
b–d Differences in OD values between PR3-ANCA positive patients and healthy controls (Mann–Whitney U test): *P value between 0.05 and 0.01, **P value
between 0.01 and 0.001; ***P value between 0.001 and 0.0001; ****P value ,0.0001
b Differences between sera of all WG patients and healthy controls
c Differences between sera of patients during their initial presentation of WG and healthy controls
d Differences between sera of patients during a relapse of WG and healthy controls
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Fig. 5. Peptide ELISA with PR3-ANCA–positive sera of patients at the time of initial presentation or during relapse of WG. Fifty overlapping
peptides spanning the entire sequence of PR3 and whole PR3 were coupled on covalink-NH plates. Wells without peptide (blank) were used as
blank values and subtracted from the optical density (OD) values obtained on wells with peptides. PR3-ANCA–positive sera from the initial
presentation of WG (d) or sera from patients with a relapse of WG (s) were used at a 50-fold dilution. On the x axis, PR3 (right segment) and
peptide numbers (left segment) are depicted according to sequence in Figure 1. On the y axis, the OD values measured at 405 nm are depicted.
The median is shown for both groups of sera.
We tested sera at a low, that is, 1:50, dilution, as further Griffith, Vasc Diffuse Lung Dis 13:256, 1996) [22]. Three
of the six epitope regions described by Williams et aldilution of the sera reduced not only background but
also specific binding. The low dilution used in this study [22] and one of the five regions described by Griffith et
al (abstract; Griffith et al, Vasc Diffuse Lung Dis 13:256,might suggest aspecific binding of healthy control sera
and possibly also of WG sera. We think that this is 1996) were not detected in this study. This discrepancy
might be due to differences in the PR3 sequence usedunlikely since background binding to wells without pep-
tide was lower than binding to peptides, and the OD for peptide construction, the ELISA method used for
peptide recognition, peptide length, or the selection ofvalues presented were derived by subtracting back-
ground binding from OD values obtained with peptides. patient and control sera.
Differences in PR3 sequence do not seem relevant, asAlso, binding occurred to a restricted number of pep-
tides, and no correlation was found between the total substitution of the polymorphic amino acids 108 and 109
[37] did not influence recognition by WG or healthyIgG levels in sera and the amount of binding to particular
peptides. In a previous study, sera of healthy controls control sera.
With respect to the ELISA system that was used, indiluted 1:800 also bound the same PR3 peptides as WG
sera [22], and another study did not find any significant our study soluble peptides were synthesized. Purity and
sequence of peptides were checked prior to use. Peptidesdifference between PR3-ANCA and healthy control sera
in recognition of PR3 peptides [21]. Thus, specific bind- were synthesized with an additional N-terminal cysteine
for subsequent coupling to activated ELISA plates, en-ing to PR3 peptides occurs by IgG both of WG patients
and of controls. abling identical coupling of each peptide to the ELISA
plate. In previous studies (abstract; Griffith, Vasc DiffuseThe observation of distinct peptide areas bound by
sera from WG patients as well as healthy controls could Lung Dis 13:256, 1996) [21, 22], peptides were con-
structed on pins or membrane and could only be checkednot be explained by differences in charge characteristics
of peptides. Peptides located around the active site are for purity and sequence after removal from the pins or
membrane. In those studies, this extra check on puritynot different from other peptides with respect to charged
amino acid components. Peptides located at the C-termi- and sequence was probably not performed. Differences
in the coupling efficiency of these peptides might influ-nus of PR3 have more positively charged amino acids,
but no binding was seen to these peptides. ence the recognition by PR3-ANCA sera.
Regarding peptide length, previous studies used pep-Four of the peptide areas recognized were bound sig-
nificantly stronger by WG sera than by sera of healthy tides of 7 amino acids with an overlap of 6 amino acids
[22] or peptides of 10 amino acids with an overlap of 8controls. These areas on PR3 corresponded to earlier
described epitope areas bound by PR3-ANCA (abstract; (abstract; Griffith, Vasc Diffuse Lung Dis 13:256, 1996).
van der Geld et al: Epitope analysis of ANCA to PR3 157
Consequently, in the first study, all possible stretches of the active site, whereas Rb anti-PR3 did not. Antibodies
7 amino acids in PR3 and in the second study all possible produced upon immunization are not induced against
9 mers of the PR3 sequence were available as peptides. conserved regions of the antigen, as this is not recognized
In the present study, using peptides of 15 amino acids as foreign. One of the most conserved region of PR3 is
long with an overlap of 10 amino acids, all 11 mers of around the active site, as the substrate specificity of the
the PR3 sequence were available. It has been shown that proteases is located there. The absence in binding to
a peptide length of 8 amino acids is sufficient to detect PR3 peptides of anti-PR3 mAbs might be due to the
all continuous epitopes [45]. Therefore, none of the pre- selection criteria of the hybridomas selecting mAbs that
viously mentioned studies, as well as our present study, bound to conformation-dependent epitopes.
should have missed a linear epitope. The peptide areas recognized in our study are located
A fourth reason to explain differences in peptide rec- at the N-terminus of PR3, around the active site H44
ognition by PR3-ANCA between the present and previ- and S176, and in the center of the primary sequence. No
ous studies relates to the selection of sera. In the current epitopes were detected at the C-terminus of PR3 nor
study, sera of WG patients during initial presentation in the signal- or prosequence. In the three-dimensional
mainly bound the peptide areas. Griffith et al also tested structure of PR3, these peptides come together around
WG patients during initial presentation of disease and the active site and have large homology with murine
PR3-ANCA of all their patients bound to the same re- PR3 [43, 44] and to a lesser extent with HLE [41]. Still,
stricted peptide regions on PR3 (abstract; Griffith et al, PR3-ANCA do not react with murine PR3 or HLE.
Vasc Diffuse Lung Dis 13:256, 1996), as was seen in our Along with the homology in primary sequence, a differ-
study. In another study, sera of WG patients were not ence in conformation of the protein could influence the
characterized based on disease manifestation or dura- recognition by antibodies. Since PR3-ANCA mainly rec-
tion, and PR3-ANCA of these patients reacted with dif- ognize conformational epitopes [20], this conformational
ferent peptide areas of PR3 [22]. Thus, the latter discrep- difference might be of crucial importance for the antigen
ancy may be explained, at least in part, by differences specificity.
in clinical state of WG patients tested. Considering that PR3-ANCA mainly recognize confor-
Apparently, in our study, PR3 peptides are bound by mational epitopes, why do we see a reproducible reaction
sera of WG patients, as well as by healthy control sera. on linear peptides? Most of the human antibodies recog-
This was also seen in previous studies [21, 22]. Indeed, nize conformation dependent epitopes [48]. Conforma-
natural antibodies reacting with a variety of self-antigens tional epitopes can be identified by x-ray crystallography
have been detected in serum of healthy individuals [46]. [49]; nevertheless, some epitopes defined by this method
In the present study, the control sera that bound to
could also be identified by overlapping linear peptides
peptides of PR3 did not recognize the whole PR3 protein,
[45]. Indeed, it has been shown that discontinuous linearwhereas sera of WG patients did (Fig. 3). Evidently,
segments of a conformational epitope can be identifiedconformation-dependent epitopes on PR3 are preferen-
using overlapping linear peptides [50–52].tially bound by WG sera, whereas linear epitopes on
In summary, our results demonstrate that sera of bothPR3 are equally bound by patient and control sera.
WG patients as well as healthy controls bind specificallyIn our study, PR3 peptides were mainly bound by sera
to a restricted number of PR3 peptides, two of whichof patients at their initial presentation of WG. Studies
are located near the active center of PR3. Four of thesein systemic lupus erythematosus (SLE) have indicated
peptide areas are significantly more strongly recognizedthat the highly diverse autoimmune response in SLE can
by sera of patients with an initial presentation of WG.originate from a single (cryptic) self-peptide without the
These data suggest that the autoimmune response to PR3need for foreign pathogens or molecular mimics [47]. In
starts from a universally present response to a restrictedthe present study, it is feasible that upon relapse of WG,
number of linear epitopes, and evolves during diseaseapart from affinity maturation, epitope spreading of
development into responses to conformational epitopes.PR3-ANCA to more conformation-dependent epitopes
has occurred, resulting in PR3-ANCA that bind linear
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